Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors.
Yap TA, O'Carrigan B, Penney MS, Lim JS, Brown JS, de Miguel Luken MJ, Tunariu N, Perez-Lopez R, Rodrigues DN, Riisnaes R, Figueiredo I, Carreira S, Hare B, McDermott K, Khalique S, Williamson CT, Natrajan R, Pettitt SJ, Lord CJ, Banerji U, Pollard J, Lopez J, de Bono JS. Yap TA, et al. Among authors: natrajan r. J Clin Oncol. 2020 Sep 20;38(27):3195-3204. doi: 10.1200/JCO.19.02404. Epub 2020 Jun 22. J Clin Oncol. 2020. PMID: 32568634 Free PMC article. Clinical Trial.
Resistance to therapy caused by intragenic deletion in BRCA2.
Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, Boyd J, Reis-Filho JS, Ashworth A. Edwards SL, et al. Among authors: natrajan r. Nature. 2008 Feb 28;451(7182):1111-5. doi: 10.1038/nature06548. Epub 2008 Feb 10. Nature. 2008. PMID: 18264088
PPM1D is a potential therapeutic target in ovarian clear cell carcinomas.
Tan DS, Lambros MB, Rayter S, Natrajan R, Vatcheva R, Gao Q, Marchiò C, Geyer FC, Savage K, Parry S, Fenwick K, Tamber N, Mackay A, Dexter T, Jameson C, McCluggage WG, Williams A, Graham A, Faratian D, El-Bahrawy M, Paige AJ, Gabra H, Gore ME, Zvelebil M, Lord CJ, Kaye SB, Ashworth A, Reis-Filho JS. Tan DS, et al. Among authors: natrajan r. Clin Cancer Res. 2009 Apr 1;15(7):2269-80. doi: 10.1158/1078-0432.CCR-08-2403. Epub 2009 Mar 17. Clin Cancer Res. 2009. PMID: 19293255
Tiling path genomic profiling of grade 3 invasive ductal breast cancers.
Natrajan R, Lambros MB, Rodríguez-Pinilla SM, Moreno-Bueno G, Tan DS, Marchió C, Vatcheva R, Rayter S, Mahler-Araujo B, Fulford LG, Hungermann D, Mackay A, Grigoriadis A, Fenwick K, Tamber N, Hardisson D, Tutt A, Palacios J, Lord CJ, Buerger H, Ashworth A, Reis-Filho JS. Natrajan R, et al. Clin Cancer Res. 2009 Apr 15;15(8):2711-22. doi: 10.1158/1078-0432.CCR-08-1878. Epub 2009 Mar 24. Clin Cancer Res. 2009. PMID: 19318498 Free article.
Functional characterization of EMSY gene amplification in human cancers.
Wilkerson PM, Dedes KJ, Wetterskog D, Mackay A, Lambros MB, Mansour M, Frankum J, Lord CJ, Natrajan R, Ashworth A, Reis-Filho JS. Wilkerson PM, et al. Among authors: natrajan r. J Pathol. 2011 Sep;225(1):29-42. doi: 10.1002/path.2944. Epub 2011 Jul 7. J Pathol. 2011. PMID: 21735447
Functional viability profiles of breast cancer.
Brough R, Frankum JR, Sims D, Mackay A, Mendes-Pereira AM, Bajrami I, Costa-Cabral S, Rafiq R, Ahmad AS, Cerone MA, Natrajan R, Sharpe R, Shiu KK, Wetterskog D, Dedes KJ, Lambros MB, Rawjee T, Linardopoulos S, Reis-Filho JS, Turner NC, Lord CJ, Ashworth A. Brough R, et al. Among authors: natrajan r. Cancer Discov. 2011 Aug;1(3):260-73. doi: 10.1158/2159-8290.CD-11-0107. Epub 2011 Aug 2. Cancer Discov. 2011. PMID: 21984977 Free PMC article.
133 results